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Background: Leukotriene B4 (LTB4) recruits and activates neutrophils. Accordingly, this leuko-
triene is involved in innate defense actions.
Objective: To examine if nasal LTB4 can produce neutrophil activity and to explore whether or
not LTB4 can condition neutrophils to exert virucidal effects in vitro and in vivo.
Methods: 1. Twenty-three healthy subjects received nasal LTB4 in a randomized and sham-
controlled design. Symptoms were scored and nasal lavages carried out. Myeloperoxidase
(MPO) and a-defensins were monitored as indices of neutrophil activity. IL-8, eosinophil cationic
protein (ECP) and a2-macroglobulin were measured as indices of pro-inflammatory cytokine
production, eosinophil activity, and plasma exudation. 2. Supernatants from neutrophils
activated by LTB4 in vitro were assayed for virucidal activity against respiratory viruses. 3.
In 38 healthy individuals, nasal inoculation with human rhinovirus-16 (HRV-16) was performed.
In a preliminary study, intervention with LTB4 was given in a randomized and controlled design.
Symptoms, virus replication, and antibody-titres were monitored.
Results: 1. LTB4 produced statistically significant increases in MPO and a-defensins, whereas IL-
8, ECP, and a2-macroglobulin were unaffected. 2. The supernatants efficiently killed human cor-
onavirus, respiratory syncytial virus, and influenza B virus. 3. HRV-16 replication was lower in
subjects receiving LTB4, but this difference failed to reach statistical significance. Common cold
symptoms and incidence of seroconversion were unaffected.
Conclusion: Nasal LTB4 induces a selective recruitment/activation of neutrophils. LTB4 can
condition neutrophils to exert virucidal effects in vitro and may reduce virus replication in vivo.
We suggest that the condition induced by LTB4 reflects an enhanced state of innate defense.
ª 2010 Elsevier Ltd. All rights reserved.171000; fax: þ46 46 2110968.
skane.se (H. Widegren).
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998 H. Widegren et al.Introduction Study designLeukotriene B4 (LTB4) is a metabolite of the 5-lipoxygenase
pathway. Original findings on the biology of this leukotriene
comprise demonstrations of its biosynthesis by, and its
potent chemotactic and activating effects on, polymorpho-
nuclear leukocytes .1e3 Accordingly, and substantiated by
a series of subsequent observations,4e11 LTB4 is regarded as
a key mediator of the innate immune system.
Information on the role of LTB4 in human airways can be
obtained through experiments involving airway challenges
with this leukotriene. Administration of LTB4 to the bron-
chial airways has been shown to increase neutrophil
recruitment,12,13 without producing exudative inflamma-
tion12 or bronchial hyperresponsiveness.14 In contrast,
there are no reports on effects of LTB4 administered to the
human nasal airway. If LTB4 selectively increases human
nasal neutrophil activity, topical administration of this
leukotriene may be employed to enhance mucosal innate
immune defense against infection.
Defensins are cationic antimicrobial peptides grouped
into a- and b-defensin subfamilies.15 a-Defensins 1-4 are
major components of neutrophil granules, whereas b-
defensins 1-4 are found in epithelial cells.16 Flamand
et al.10 recently demonstrated that intravenous adminis-
tration of LTB4 to monkeys produced increased plasma
levels of a-defensins and that these levels could exert
antimicrobial effects ex vivo. Whether or not topical
administration of LTB4 affects the nasal mucosal output of
a-defensins is unknown.
In this study, we examined dose- and time-dependent
effects of nasal administration of LTB4 in healthy subjects
on symptoms, nasal peak inspiratory flow (PIF), and select
nasal lavage fluid indices. Accordingly, we monitored the
neutrophil granule protein myeloperoxidase (MPO) and a-
defensins as indices of neutrophil activity. Interleukin-8 (IL-
8) was analyzed in order to explore whether or not any
neutrophil active effect of LTB4 involved this pro-inflam-
matory cytokine. Eosinophil cationic protein (ECP) and a2-
macroglobulin were monitored as indices of eosinophil
activity and plasma exudation, in order to explore whether
or not LTB4, or any LTB4-produced neutrophil activity, had
any consequence to the nasal mucosa in terms of producing
eosinophil, exudative inflammation. In this study, we also
studied whether or not exposure of neutrophils to LTB4 in
vitro induced virucidal effects against respiratory viruses:
human coronavirus, human respiratory syncytial virus
(RSV), and human influenza B virus. Finally, in a preliminary
experiment involving healthy subjects, we examined
effects of LTB4 on human rhinovirus-16 (HRV-16) induced
virus replication, seroconversion, and symptoms.Methods
This study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Lund
University (Reference numbers 522/06 and 198/09). All
patients provided written informed consent for the
collection of samples and subsequent analysis.1. In healthy subjects, nasal challenges with LTB4 were
carried out in a double-blinded, randomized, sham-
controlled, and crossover design. Nasal lavages were
carried out and IL-8, a-defensins, MPO, ECP, and a2-
macroglobulin were measured.
2. In experiments in vitro, possible virucidal effects of
supernatants of neutrophils conditioned by LTB4 were
examined on human coronavirus, RSV, and influenza B
virus.
3. In healthy individuals, nasal inoculation with HRV-16
was carried out. Intervention with LTB4 was adminis-
tered in a double-blinded, randomized, controlled, and
parallel group design. Nasal symptoms, virus replica-
tion, and neutralizing antibody-titres were monitored.Effects of LTB4 on the human nasal mucosa in vivo
Subjects
Twenty-three subjects (11 female, 12 male, aged 21e29
years) were recruited. Inclusion criteria were a negative
skin-prick test to relevant aeroallergens. Exclusion criteria
were allergic rhinitis, other nasal disease (structural abnor-
malities, rhinosinusitis, and polyposis), chronic disease and/
or on-going drug treatment, and pregnancy or lactation. The
subjects were without medication and had been so for at
least fourweeks prior to the study. Nomedication except the
study drug and occasional use over-the-counter pain
relievers were allowed during the course of the study.
Challenges
All challenges (and all lavages) were given to the right hand
side of the nasal cavity. Sham solution (isotonic saline con-
taining 10 mM glycine/sodium hydroxide buffer, pH 10.5),
used as control challenge, and two doses of LTB4 (2.0 and
20 mg) dissolved in sham solution were given in a randomized
order. The challenges were given as single actuations using
a spray-device delivering 100 ml per actuation. The washout
time between the administrations was at least one week.
Clinical measurements
Symptoms, nasal peak inspiratoryflow(PIF), andnasal lavages
were carried out before each challenge as well as 1 and 4 h
thereafter. The symptoms blocked nose, runny nose, and
irritation were scored by the subjects on a four-graded scale:
0 Z no symptoms, 1 Z mild symptoms, 2 Z moderate
symptoms, 3 Z severe symptoms. The number of sneezes
were counted and transformed into a score: 0Z 0 sneezes,
1Z 1e4 sneezes, 2Z 5e8 sneezes, 3Z more than 9 snee-
zes.17 The four scores of blocked nose, runny nose, irritation,
and sneezes were then added to a total nasal symptom score
(TNSS).17 Nasal PIF were measured using a PIF-meter
(Clement-Clarke,Harlow,U.K.).Oneachoccasion, thebest of
three PIF-recordings were used in the analysis.
Nasal lavages
A pool-device was used for isotonic saline lavage of the nasal
mucosa as describedpreviously.18 The volumeof thepool-fluid
was 14 ml and the dwell time 5 min (This high-volume lavage
LTB4 conditions neutrophils to exert antiviral effects 999retrieves nasal mucosal surface liquids that are diluted in the
process. The degree of dilution is likely similar at baseline and
post challenge observations.) The lavages were carried out
before each challenge as well as 1 and 4 h thereafter.
Analyses
LTB4 (Cayman Chemicals, Ann Arbour, MI; detection limit
13 pg/ml), MPO (Diagnostic Development, Uppsala,
Sweden; detection limit 1.6 ng/ml), IL-8 (Invitrogen, Bur-
lington, Ontario, Canada; detection limit 5 pg/ml), and a-
defensins (HyCult Biotechnology, Uden, The Netherlands;
detection limit 50 pg/ml) were measured by ELISA. ECP was
measured using a fluoroimmunoassay (Pharmacia Diagnos-
tics, Uppsala, Sweden; detection limit 2.0 ng/ml). a2-
Macroglobulin was measured using a radioimmunoassay
(detection limit 7.8 ng/ml).18
Effects of LTB4-conditioned neutrophils on
respiratory viruses in vitro
Isolation of human polymorphonuclear leukocytes (PMN)
From a separate group of healthy volunteers, venous blood
was collected in tubes containing heparin and PMNs were
isolated as described previously.19 The PMN-suspension
contained mainly neutrophils (95%) with eosinophils as the
major contaminant. Cell viability, as measured by trypan
blue exclusion, was always greater than 98%. PMN were re-
suspended to 10x106 cells/ml in M199 medium without
serum or antibiotics.
Stimulation of human PMNs and virucidal assays
Freshly isolated human PMNs were pre-incubated (10x106/
ml) in M199 medium containing 10 mM of cytochalasin B for
10 min at 37 C after which LTB4 was added to each tube to
various concentrations (0, 1, 10, and 100 nM). Incubations
were stopped after 5 min by transferring tubes into an ice/
water bath. Cell suspensions were centrifuged (250 g,
10 min, 4 C) and cell-free supernatants were collected and
assayed for virucidal activity as follows. Preparations of
infectious viruses (100 ml), including human Coronavirus
(strain 229E, provided by Dr. P. Talbot, INRS-Institut Armand
Frappier, Laval, Canada), human RSV (strain A2, obtained
from the American Type Culture Collection [Manassas, VA]),
and Influenza B virus (Harbin strain, provided by Dr. G.
Boivin, CHUQ Research Center, Laval, Canada), were added
to 100 ml of PMN-supernatants and the mixtures were
incubated at 37 C for 1 h. The volumes were adjusted to
1.0 ml with culture medium and the mixtures were added
to cell monolayers to determine infectivity by standard
assays 3e6 days later.20 Culture supernatants containing
10 mM cytochalasin B and 100 nM LTB4 without PMNs or
supernatants from PMNs stimulated with a control solution
(ethanol) were used as negative controls. Results were
expressed as mean TCID50 þ SD from one experiment
representative of at least two independent experiments.
Effects of nasal LTB4 on HRV-16 infectivity
Subjects
Seventy-seven healthy subjects (45 female, 32 male, aged
19e31 years) were enrolled for screening. Inclusion andexclusion criteria were identical to those of the LTB4
challenge study described above. In addition, individuals
with detectable levels of serum neutralizing antibodies to
HRV-16 were excluded. Accordingly, 40 subjects (21
female, 19 male, aged 19e30 years) were randomized. Of
these subjects, one was excluded from the analysis due to
wild type HRV-16 infection at the day of the inoculation
(i.e., a positive qPCR prior to inoculation) and one due to
symptomatic upper respiratory tract infection of unknown
cause on the same day. Ultimately, the control group
comprised ten females and ten males (aged 21e30 years)
and the LTB4-group nine females and nine males (aged
19e28 years).
LTB4 intervention
LTB4 (dissolved in 10 mM glycine/sodium hydroxide buffer,
pH 10.5) was administered as intervention in a double-
blinded, randomized, controlled, and parallel group design.
The dose of LTB4 was 2.0 mg per nasal cavity and it was
given twice daily for four days. The intervention started 2 h
prior the HRV-16 inoculation. Control solution (“placebo”)
was isotonic saline containing 10 mM glycine/sodium
hydroxide buffer, pH 10.5. A nasal spray-device delivering
100 ml per actuation was used for the administration. In
order to assure compliance, the investigators performed
the administrations at visits to the clinic.
HRV-16 inoculation
On study day 1, 10 TCID50 (tissue culture infective dose 50%
in 0.5 ml isotonic saline) of HRV-16, initially harvested and
cultivated by Bardin et al.21 was mixed with 0.5 ml isotonic
saline and administered to each nasal passage (0.5 ml per
side) using a mucosal Atomization Device (No. 40-0124,
Wolfe Tory Medical, Salt Lake City, UT) attached to a 2 ml
syringe. The inoculation took place 2 h after the first
administration of LTB4/control solution.
Symptom scores
Symptoms were registered in the morning on study days
1e6, before the lavage procedure (below) and before
administration of LTB4/control solution. Nasal secretion,
blockage, nasal irritation, headache, sinus ache, sore
throat, and hoarseness were scored by the subjects on
a four-graded scale: 0Z no symptoms, 1Zmild symptoms,
2 Z moderate symptoms, 3 Z severe symptoms. These
seven scores were added and divided by seven to a mean
symptom score (range 0e3).
Nasal lavages
Nasal lavages were performed every morning on study days
1e6, between the symptom registration and LTB4/control
administration. The subject tilted the head back 90,
closed the soft palate (in order to avoid displacement of
saline to the throat), and 1.25 ml of sterile saline was
instilled into each nasal cavity using a sterile syringe. After
three seconds, the head was tilted forward and the lavage
fluid was collected into a sterile test tube via a funnel. The
fluid was centrifuged and the supernatant, except the part
bound for qPCR analysis (w200 ml), was mechanically
homogenized (Yellow Line DI 18 Basic [IKA, Staufen,
Germany]). Finally, the fluid was aliquoted and stored at
70 C.
1000 H. Widegren et al.Analyses
HRV-16 in the nasal lavage fluid was detected through qPCR
according to Message et al.21 Analysis of neutralizing HRV-16
antibodies in serum was also performed as described by
Message et al.22 Seroconversion was defined as a four-fold (or
more) increase in HRV-16 neutralizing antibodies titer
betweenstudyday1andanobservationpoint6e8weeks later.
IL-8 was measured in the nasal lavage fluid as a surrogate
marker for inflammationassociatedwith theHRV-16 infection.
Statistics
For the LTB4 challenge study, differences in symptoms and
levelsofanalytesbetween theLTB4challengesandshamwere
analyzedusingtheFriedmantestand theWilcoxonsigned rank
test. For the in vitro study, the T-test withWelch’s correction
was used. For the hrv-16-inoculation study, differences
between the intervention groups were analyzed with Fisher’s
exact test (for serology data) and the Mann Whitney U-test.
Paired comparisons within each group were analyzed using
the Friedman test and the Wilcoxon signed rank test. P-
values < 0.05 were considered statistically significant. No
power calculations were carried out for these studies as they
were exploratory in nature and since no similar studies have
been reported to provide data on which to perform such
calculations.Nonparametricmethods for comparisonwere for
the LTB4 challenge study and in the hrv-16-inoculation study
because the data were not normally distributed.
Results
Effects of LTB4 on the human nasal mucosa in vivo
Nasal administration of LTB4, in the dose-range of
2.0e20 mg, did not produce any nasal symptoms during the
4-h follow-up period (Table 1). Moreover, nasal PIF was
unaffected by the LTB4 exposure (Table 2).
LTB4 was measured in nasal lavage fluids in order to esti-
mate its retention in the nose (Table 3). LTB4wasmeasurable
in lavages of sham-challenged subjects at a median level of
0.46 ng/ml and did not vary much in subsequent lavages.
Levels of LTB4 increased at 1 h following challenge with 2.0
and 20 mg compared with sham (both p < 0.001). After 4 h,
levels had returned to near baseline levels.
MPO was detected in all nasal lavage fluid samples (i.e.,
207/207 observations). Levels of MPO increased following
challenge with 2.0 mg LTB4, but the subsequent greater
dose of 20 mg did not further elevate the levels (Fig. 1A).
The increases were statistically significant for both doses ofTable 1 Nasal symptoms after LTB4 challenge.
LTB4 (mg) Sneezes (0e3) Secretion (0e3)
Prior 1 h 4 h Prior 1 h 4 h
0 (Sham) 0 (0) 0 (0) 0 (0) 0 (1.0) 0 (1.0) 0 (1
2.0 0 (0) 0 (0) 0 (0) 0 (1.0) 0 (1.0) 0 (0
20 0 (0) 0 (0) 0 (0) 0 (1.0) 0 (0) 0 (1
Median levels (interquartile ranges) of symptoms recorded prior to nas
thereafter. LTB4 did not produce any rhinitis symptoms or any nasal irr
point (all statistically non-significant).LTB4 at 1 h post challenge (p < 0.01 and 0.05) as well as at
4 h (both p < 0.05) (c.f. sham).
A five-fold increase in levels of a-defensins by LTB4
(2.0 mg) was recorded at 1 h following its administration
(p < 0.05) (Fig. 1B). Similarly, the levels were increased at
4 h post challenge as well as at both observation points
following challenge with LTB4 (20 mg), but these effects
failed to reach statistical significance. In contrast to other
analytes, where gradually lower levels were recorded over
time following sham challenge (see below), increased
levels of a-defensins were observed 1 and 4 h post sham
challenge (c.f. prior to challenge) (p < 0.0001 and
p Z 0.0003). This baseline drift produced by the alkaline
buffer itself suggests that the sensitivity to detect LTB4-
induced changes in a-defensins was poor.
Levels of IL-8 were not affected by LTB4 (c.f. sham)
(Table 4). ECP and a2-macroglobulin were low prior to
challenge and LTB4 did not increase the levels of these
analytes at any of the observation points (c.f. sham) (Table
4). Rather, the repeated lavages produced gradually lower
levels of ECP and a2-macroglobulin, which was reflected by
the fact that these markers were undetectable in 123/207
and 120/207 observations, respectively.
Focusing on the nasal lavage series conducted following
sham challenge, it was evident that the repeated lavages
gradually lowered the analyte levels (except for a-defen-
sins). For example, MPO featured a 75% reduction between
the observation pre- and 4 h post challenge. This finding
emphasizes the necessity of the sham-controlled design of
the experiment.
Effects of LTB4-conditioned neutrophils on
respiratory viruses in vitro
In the in vitro experiments, isolated PMNs were exposed to
varying concentrations of LTB4 and cell-free supernatants
were collected and incubated with human coronavirus
(Fig. 2A), human RSV (Fig. 2B), and human influenza B virus
(Fig. 2C). The results indicated that the supernatants
significantly reduced the infectivity of these viruses when
concentrations of LTB4 of 10 nM and 100 nM were used to
condition neutrophils, but not at 1 nM.
Effects of nasal LTB4 on HRV-16 infectivity
Focusing on the control group as a whole, significant virus
replication was observed three to five days following HRV-16
inoculation (Fig. 3A). Furthermore, this group presented
mild, yet statistically significant, nasal symptoms of commonBlockage (0e3) Irritation (0e3)
Prior 1 h 4 h Prior 1 h 4 h
.0) 0 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
) 0 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
.0) 0 (1.0) 0 (0) 0 (1.0) 0 (0) 0 (0) 0 (0)
al challenge with sham and two doses of LTB4 as well as 1 and 4 h
itation. Comparisons are made with sham challenge at each time-
Table 2 Nasal PIF after LTB4 challenge.
LTB4 (mg) Nasal PIF (l/min)
Prior 1 h 4 h
0 (Sham) 150 (100) 120 (65) 140 (70)
2.0 140 (80) 130 (50) 140 (70)
20 140 (60) 140 (80) 130 (80)
Median levels (interquartile ranges) of nasal PIF recorded prior to nasal challenge with sham and two doses of LTB4 as well as 1 and 4 h
thereafter. LTB4 produced a minor but non-significant improvement in nasal PIF 1 h post challenge. Comparisons are made with sham
challenge at each time-point (all statistically non-significant).
LTB4 conditions neutrophils to exert antiviral effects 1001cold (Fig. 3A). Twelve of the 20 control subjects sero-
converted. Six subjects had very convincing evidence of virus
replication (i.e., more than 100,000 copies/ml lavage on
three consecutive days) and the response peaked three days
after inoculation. This group also featured greater levels of
IL-8 in nasal lavage fluids on day four following inoculation
compared with the remainder of the group (median levels
7393 pg/ml and 649 pg/ml, respectively, p < 0.05). Eight of
the 20 control subjects were negative for virus on all tested
days. One control subject who was positive for virus did not
seroconvert and, conversely, one subject whowere negative
for virus did seroconvert.
LTB4 intervention was associated with 46% lower viral
shedding compared with controls (over the entire post-inoc-
ulation period), but this change failed to reach statistical
significance (Fig. 4A). However, of the top five virus-shedding
individuals, four were found in the control group; LTB4
reduced clearly positive infections by 27% (defined as
substantial virus replication:>100,000 copies/ml lavage fluid
over three consecutive days in combination with seroconver-
sion); LTB4 reducedhigh-gradeviral shedding (>106copies/ml
lavage) by 35%. Symptom scores did not differ between the
groups (Fig. 4B). Seroconversion occurred in eleven of the 18
subjects receivingLTB4.Nasal lavagefluid levels of IL-8didnot
differ between the groups (data not shown).
Discussion
This study demonstrates that nasal administration of LTB4
selectively increases local neutrophil activity as reflected
by increased levels of MPO and a-defensins in nasal mucosal
surface liquids. Furthermore, it shows that LTB4 can
condition neutrophils to produce factors that exert
virucidal effects towards key respiratory viruses: humanTable 3 Lavage levels of LTB4 after LTB4 challenge.
LTB4 (mg) LTB4 (ng/ml)
Prior
0 (Sham) 0.46 (0.18)
2.0 0.50 (0.25)
20 0.47 (0.59)
Median levels (interquartile ranges) of LTB4 in nasal lavages obtained p
1 and 4 h thereafter. Levels of LTB4 significantly increased 1 h follow
administered dose of LTB4 was retrievable by lavage at 4 h post cha
sham challenge at each time-point (*** denotes p < 0.001.)coronavirus, RSV, and influenza B virus. Finally, in
a preliminary experiment involving healthy humans, the
study explores whether or not nasal administration of LTB4
affects the outcome of a low-dose HRV-16 inoculation. The
observations are of interest with regard to how LTB4
amplifies innate immune responses.
Nasal administration of LTB4 increased the lavage fluid
levels of MPO (this study), indicating increased neutrophil
activity. A statistically significant response was detected
already at the first of the employed doses (i.e., 2.0 mg). The
second dose produced a response of similar magnitude
despite the fact that it was ten times greater, suggesting
a flat response curve in this particular dose-range. The
effect was numerically greater 1 h post challenge than at
4 h, indicating a rapid and transient response. Our finding
that LTB4 was rapidly cleared from the nasal mucosa (w1%
retrievable by lavage within 1 h of nasal administration)
might account for this effect profile. In agreement with the
present findings, Martin et al.12 in a study involving healthy
subjects, showed that bronchial instillation of 10 ml of
a 5x107 M solution of LTB4 (w1.7 mg) increased neutrophil
numbers in BAL-fluids. Taken together, the above obser-
vations indicate that LTB4 can recruit and activate
neutrophils in human airways, including the nasal airway.
A heightened neutrophil activity was also suggested by
the present observations on nasal lavage fluid levels of a-
defensins. The levels were increased by LTB4 by a median
5-fold at 1 h following challenge with 2.0 mg LTB4. a-
Defensins were consistently increased also at the other
observation points (c.f. sham), but these changes failed to
reach statistical significance. The wide distribution of data
for a-defensins, and the fact that the alkaline buffer (sham)
appeared to increase the baseline, might have contributed
to our failure to detect a specific LTB4-induced effect more1 h 4 h
0.48 (0.19) 0.42 (0.21)
1.16 (2.23)*** 0.42 (0.28)
17.45 (23.15)*** 0.69 (1.28)***
rior to nasal challenge with sham and two doses of LTB4 as well as
ing challenges with 2 and 20 mg LTB4. Approximately 1% of the
llenge, approaching baseline values. Comparisons are made with
Figure 1 LTB4 produces increased nasal lavage levels of MPO and a-defensins; Levels of MPO (A) and a-defensins (B) in nasal
lavages obtained prior to challenge with sham and two doses of LTB4 as well as 1 and 4 h thereafter. LTB4 increased levels of MPO
and a-defensins: these changes reached statistical significance for MPO at 1 as well as 4 h post challenge for both doses and for a-
defensins at 1 h post challenge for LTB4 (2.0 mg). Comparisons were made with sham challenge at each time-point. Note that the
repeated lavages produced gradually lower levels of MPO following sham challenge (as for IL-8, ECP, and a2-macroglobulin: Table
4), whereas the sham challenge increased the levels of a-defensins. Data are expressed as median  IQR (n Z 23). ) Denotes
p < 0.05 and )) p < 0.01, paired comparisons.
1002 H. Widegren et al.convincingly. However, observations by Flamand et al.10,23
indicated increased plasma levels of a-defensins in
monkeys and humans following intravenous administration
of LTB4. Furthermore, in the present study, neutrophils
activated in vitro by LTB4 released factors with virucidal
activities against human coronavirus, RSV, and influenza B
virus: these results extend previous observations demon-
strating the release of antimicrobial compounds (including
a-defensins) following stimulation of neutrophils with
LTB4.10 Taken together, the present observations suggest
that a-defensins are a part of the innate defense system of
the upper respiratory tract and that this feature can be
enhanced by nasal administrations of LTB4.
IL-8 is a pro-inflammatory cytokine that attracts
neutrophils: e.g., intranasal administration of recombinant
human IL-8 increases neutrophil numbers in nasal smears.24Table 4 Lavage levels of IL-8, ECP, and a2-macroglobulin after
LTB4 (mg) IL-8 (pg/ml) ECP (ng/ml
Prior 1 h 4 h Prior
Sham 171 (244) 79 (130) 50 (88) 0 (4.5)
2.0 136 (188) 94 (103) 67 (82) 0 (6.2)
20 148 (202) 81 (106) 65 (86) 0 (3.5)
Median levels (interquartile ranges) of analytes in nasal lavages obta
well as 1 and 4 h thereafter. LTB4 failed to affect the levels of IL-
challenge at each time-point (all statistically non-significant).In this study, nasal lavage fluid levels of IL-8 were unaf-
fected by topical administration of LTB4. Accordingly, the
recorded increase in neutrophil activity (i.e., elevated
levels of MPO) might not involve an IL-8-dependent mech-
anism. This is in contrast to conditions characterized by
increased neutrophil activity, e.g., viral infections, where
IL-8 is thought to be central in mediating a neutrophil
response.18 Conversely, the present observations are in
keeping with the notion that neutrophil activity mediated
by LTB4 may not be a disease-like mechanism, but rather
a feature of the innate immune defense system.
In vitro observations suggest the possibility that LTB4
can act as chemoattractant for IL-5-primed eosinophils25
and activate eosinophils.26 Also, eosinophils entering
human bronchial airways following allergen challenge are
chemotactically desensitized to LTB4,27 suggestingLTB4 challenge.
) a2-macroglobulin (mg/ml)
1 h 4 h Prior 1 h 4 h
0 (3.9) 0 (2.2) 0.2 (0.2) 0 (0.1) 0 (0.1)
2.0 (5.0) 0 (3.0) 0 (0.2) 0 (0.2) 0 (0.1)
0 (6.2) 0 (3.8) 0 (0.3) 0 (0.2) 0 (0.1)
ined prior to nasal challenge with sham and two doses of LTB4 as
8, ECP, and a2-macroglobulin. Comparisons are made with sham
Figure 2 LTB4 conditions neutrophils to exert antiviral effects; Supernatants from neutrophils conditioned with LTB4 produced
virucidal effects against human coronavirus (A), RSV (B), and influenza B virus (C). Control experiments indicated that the effect
was specific for the interaction between LTB4 and neutrophils. Data are expressed as mean TCID50 þ S.D. from one experiment
representative of at least two independent experiments. ) Denotes p < 0.05.
LTB4 conditions neutrophils to exert antiviral effects 1003exposure to LTB4 in vivo. Together, these observations
suggest an association between LTB4 and eosinophil
activity. In contrast, in the present study, while LTB4
increased the generation of MPO, lavage fluid levels of ECP
were unaffected, indicating that nasal granulocyte activity
mediated by LTB4 in the human nasal airway does not
involve eosinophils. We cannot exclude the possibility that
LTB4 may increase eosinophil activity if elevated numbers
of eosinophils would be present at the time of challenge,
e.g., as in on-going allergic rhinitis or asthma (LTB4 has
been administered to bronchial airways of patients with
mild asthma, but without focus on airway eosinophil
activity14). However, so far, available human in vivo
observations with LTB4 argue against a role for LTB4 as
a pro-eosinophil factor. For example, a LTB4 receptor
antagonist had no effects on allergen-induced eosinophilia
in asthma.28Figure 3 The control subjects presented viral replication and co
with HRV-16. These subjects presented HRV-16 replication (peaking
mild nasal symptoms of the common cold (B). Data are expressed
p < 0.01, paired comparisons with baseline levels prior to inoculatPlasma exudation is a key feature of airway inflammation.
Theprocess comprisesextravasationand luminal entry of bulk
plasma, including high molecular weight proteins such as a2-
macroglobulin (725 kDa). It can bemonitored through analysis
of plasma proteins in mucosal surface liquids.29 Accordingly,
in airway diseases characterized by inflammation, levels of
plasmaproteins innasal lavage- andBAL-fluidsmay reflect the
degree of on-going inflammation.29 In this, lavage fluid levels
of a2-macroglobulin were unaffected following LTB4 chal-
lenge, indicating that this leukotriene does not exert plasma
exudation producing effects in human nasal airways at the
dose used. In contrast, Bende et al.30 in a study on anes-
thetized rabbits, reported increased vascular permeability
following nasal challenge with LTB4. We have no specific
explanation for the discrepant findings, but species differ-
ences may be one reason.29 The present observation is in
agreement with observations in man by Martin et al.12:mmon cold symptoms; Data from control subjects inoculated
three days following inoculation), as indicated by qPCR (A), and
as mean  SEM (n Z 20). ) Denotes p < 0.05 and )) denotes
ion.
Figure 4 Comparison of viral replication and common cold symptoms between the two groups; Virus replication (A) and nasal
symptoms (B) from the LTB4 and control groups. Virus replication was lower in the LTB4-group, but this difference (c.f. control
group) failed to reach statistical significance overall as well as at all time-points. Nasal symptoms of the common cold were mild an
unaffected by LTB4. Data are expressed as mean  SEM (n Z 20: control and 18: LTB4).
1004 H. Widegren et al.unaffected levels of albumin as well as total protein in BAL-
fluids were observed in healthy subjects following segmental
LTB4 challenge. Available observations in man thus suggest
that LTB4, indoses thatproduce increasedneutrophil activity,
does not produce exudative inflammation.
Bachert et al.31 reported an interesting temporal rela-
tionship between increased levels of MPO in nasal secretions
and a fall in virus replication in naturally acquired infections.
The finding suggests that a heightened neutrophil activity is
beneficial in the context of viral exposure of the upper
respiratory tract. This is indirectly supportedby thepresent in
vitro observations that LTB4-activated neutrophils produce
factors active against respiratory viruses. Moreover, previous
studies have implicated neutrophils as an important player in
the response to such infections,32e35 and Gaudreault et al.
demonstrated that i.v. LTB4 upregulated antimicrobial
peptides and reduced viral load in influenza infected mice in
vivo.36 In linewith this, we employedHRV-16 inoculations and
explored the effect of repeated nasal administration of LTB4
on rhinovirus infections in a preliminary study. The dose
investigated (2.0 mg) was chosen based on the present dose-
response experiments involving LTB4, whereby increased
neutrophil activity was induced without producing exudative
inflammation or symptoms. We elected to use a low-dose (10
TCID50) virus challenge as this has been shown to be effective
in inducingcolds inCOPD-subjects.37 Furthermore,webelieve
this to be a better model of natural transmission of virus
infections (where inoculation occurs with very small amount
of virus followed by replication up to high titreswith resultant
symptom induction) than would be the case with high-dose
challenge model where inoculation with doses as high as
10,000 TCID50 is performed.
22
In this study significant virus replication was observed
three through five days following HRV-16 inoculation in the
control group as a whole. Furthermore, this group pre-
sented mild, yet statistically significant, nasal symptoms of
common cold and a minor increase in nasal mucosal output
of IL-8. However, unlike high-dose challenge where w90%
of subjects become infected,22 only 12/20 control subjects
seroconverted and 12/20 had evidence of virus replicationwith 6/20 having high virus titres. These lower than
expected numbers of infected subjects likely hampered our
ability to detect statistically significant effects on viral
outcomes. Nonetheless, several of the present observations
suggested that LTB4 might have affected virus replication.
For example, the degree of viral shedding was reduced by
nearly 50% in the LTB4-group compared with the control
group. Also, of the top five virus-shedding individuals, four
were found in the control group. However, likely in part
reflecting an inferior power of the parallel group design, as
well as the issue with numbers of infected subjects, the
changes failed to reach statistical significance. While these
data, together with our observations in vitro, were prom-
ising, symptoms and incidence of seroconversion were not
affected by LTB4. Accordingly, LTB4 did not provide
convincing evidence of a preventive treatment for common
cold infections caused by HRV-16. Further studies with
greater numbers of infected subjects, and properly pow-
ered using data from the present study, are warranted to
explore whether or not nasal administration of LTB4 can be
useful to prevent or treat upper respiratory tract infec-
tions. Also, it would be of interest to explore effects of
LTB4 in bacterial infections, where neutrophil phagocytosis
is of key importance to clear infections.37
We conclude that nasal administration of LTB4 in the
present dose-range produces increased nasal neutrophil
activity, potentially reflecting an enhanced state of innate
immune defense,without being associatedwith any apparent
untoward effects. Furthermore, LTB4 has a potential to exert
antimicrobial effects on respiratory tract infections.
However, further studies in which LTB4 intervention is
undertaken and where effects on respiratory infections are
studied in vivo are warranted to confirm this hypothesis.Conflict of interest statement
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